Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-DOTATOC in somatostatin receptor expressing tumors
NCT03013387Phase 2Withdrawn
- Start
- Jan 2017
- Primary completion
- Oct 2018
- Modality
- Peptide-Drug Conjugates
01
Overview
A Phase 2 trial of yttrium-90 edotreotide in Neuroendocrine Neoplasm (NEN), meningioma, neuroblastoma, medulloblastoma. Planned start Jan 2017; status: withdrawn.
02
Drugs
yttrium-90 edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)meningiomaneuroblastomamedulloblastoma
Beyond the preview
Go deeper on NCT03013387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013387.